HIMS Stock's Valuation Looks Reasonable As stated above, HIMS stock's valuation looks reasonable now. Let's use a reverse DCF, as I did in my HIMS article from November, to figure out how much ...

With Hims & Her's main source of growth set to be extinguished, Citi analysts said its full-year guidance appears "aspirational." ...

Many treatments are available, and with the popularity of online and mail-order services in recent years, two leaders are BlueChew and Hims. Both companies offer different ED treatments and a ...

A personalized GLP-1 treatment tailored to an individual would yield better results at a lower price (since Hims owns its compounding pharmacies). If a woman successfully loses weight using Hims ...

Plus, the company offers free shipping on all prescriptions. To use Hims, you start by filling out an initial consultation form with basic information that took anywhere from 5 to 8 minutes.

Hims & Hers Health (HIMS) is jumping 15% after the company announced that it had made an acquisition which will allow it to launch at-home lab testing. Hims & Hers owns and operates an online ...

Hims and Roman are telehealth companies that sell prescription and nonprescription products to treat erectile dysfunction (ED), hair loss, and premature ejaculation (PE). Both ED and hair loss can ...

Four-star-rated analyst Daniel Grosslight at Citi reiterated his Sell rating on Hims & Hers Health (HIMS) stock yesterday, ...

"Access to richer data allows us to deepen the insights that providers can use on our platform to guide their clinical decisions for each individual patient," said Dr. Patrick Carroll, Hims & Hers ...